Clinical trials: Peripheral Neuropathy
- Condition Peripheral Neuropathy
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Diabetic Neuropathy Peripheral
Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy
Part A of this trial is a multi-center, prospective, double-blinded, sham-controlled, randomized clinical trial. Part A will evaluate PEMF treatment compared to sham treatment in patients with painful diabetic distal symmetric…
- Trial name
- RELIEF (NCT03455543)
- Testing
- Active Provant Therapy System
- Where
- 18 sites in United States
- Volunteers
- 182 people
- Sponsor
- Regenesis Biomedical, Inc.
Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group 3-arm study to investigate 2 different doses of subcutaneous (SC) IgPro20 compared with placebo for maintenance treatment of…
- Trial name
- NCT01545076
- Testing
- IgPro20 (low dose), IgPro10, IgPro20 (high dose)
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 208 people
- Sponsor
- CSL Behring
Pain, Diabetic Neuropathy
Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy
The purpose of this study is to investigate if AZD2066 can relieve the pain arising from painful diabetic neuropathy compared to placebo.
- Trial name
- NCT00857623
- Testing
- AZD2066
- Where
- 19 sites in United States
- Volunteers
- 127 people
- Sponsor
- AstraZeneca
Post-herpetic Neuralgia
Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)
This study was designed to characterize dose response, and evaluate safety and efficacy of three different doses of EMA401 compared to placebo in patients with post-herpetic neuralgia (PHN).
- Trial name
- EMPHENE (NCT03094195)
- Testing
- EMA401
- Where
- 58 sites in Australia, Austria and 17 more
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
This was a 4-part (Part A, Part B, Part C and Part D), Phase I/IIa, multi-center, open label, study in pediatric subjects with refractory or recurrent tumors.
- Trial name
- NCT02124772
- Testing
- Trametinib, Dabrafenib
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
Painful Diabetic Neuropathy, Diabetes
A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy
Study CLO-311 is a multicenter, open-label, single-arm study to assess the long-term use of Clonidine Gel in the treatment of pain associated with PDN.
- Trial name
- NCT02355158
- Testing
- clonidine hydrochloride topical gel, 0.1%
- Where
- 20 sites in United States
- Volunteers
- 197 people
- Sponsor
- BioDelivery Sciences International
Arthroscopy, Bunionectomy
A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Minor Surgical Procedures
The purpose of this study is to determine the safety, tolerability, and efficacy of AQUAVAN® Injection when used for mild-to-moderate sedation in patients undergoing minor surgical procedures.
- Conditions
- Arthroscopy, Bunionectomy, Osteotomy, Carpal Tunnel
- Trial name
- NCT00209560
- Testing
- fospropofol disodium
- Volunteers
- 168 people
- Sponsor
- Eisai Inc.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The intent of this study is to demonstrate the efficacy and safety of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in newly or previously diagnosed CIDP subjects.
- Trial name
- ICE (NCT00220740)
- Testing
- Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 32 sites in United States, Argentina and 8 more
- Volunteers
- 117 people
- Sponsor
- Grifols Therapeutics LLC
Advanced Stage Solid Tumors
ATRi Transition Rollover Study
The main purpose of the study was to monitor the safety of participant receiving long-term treatment of Berzosertib as monotherapy.
- Trial name
- NCT03309150
- Testing
- Berzosertib
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Neuropathic Pain
A Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin
This study is being conducted as a regulatory requirement post initial marketing authorization. This is primarily a safety study.
- Trial name
- PAINS (NCT00892008)
- Testing
- Pregabalin
- Volunteers
- 2,278 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Neuropathy
Effect of the Erchonia® EVRL OTC™ for the Relief of Diabetic Peripheral Neuropathy Foot Pain
This study is to see if applying red and violet low-level laser light can help to reduce foot pain associated with diabetic peripheral neuropathy,
- Trial name
- NCT05091047
- Testing
- Erchonia EVRL
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Erchonia Corporation
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
The aim of this study is to learn more about the following treatment options in adults with CIDP: Subcutaneous self-infusion with HyQvia. Intravenous infusion with Gammagard/Kiovig.
- Trial name
- NCT02549170
- Testing
- HYQVIA, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C
- Where
- 83 sites in United States, Argentina and 20 more
- Volunteers
- 138 people
- Sponsor
- Baxalta now part of Shire
Painful Diabetic Neuropathy
Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)
The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).
- Trial name
- EMPADINE (NCT03297294)
- Testing
- EMA401
- Where
- 64 sites in Australia, Austria and 14 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Pain, Peripheral Neuropathy
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin, bortezomib and ixabepilone.
- Conditions
- Pain, Peripheral Neuropathy, Neuropathic Pain
- Trial name
- TTX-CINP-201 (NCT01655823)
- Testing
- Tetrodotoxin
- Where
- 23 sites in United States
- Volunteers
- 125 people
- Sponsor
- Wex Pharmaceuticals Inc.
Painful Diabetic Neuropathy
A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy
The purpose of this study is to determine if lacosamide (SPM 927) is safe if taken for a longer period of time and whether it continues to work well to treat pain.
- Trial name
- NCT00220337
- Testing
- Lacosamide
- Where
- Germany
- Volunteers
- 371 people
- Sponsor
- UCB Pharma
FAP, Familial Amyloid Polyneuropathy
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
The purpose of this study is to evaluate the efficacy and safety of inotersen given for 65 weeks in participants with Familial Amyloid Polyneuropathy (FAP).
- Conditions
- FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin
- Trial name
- NCT01737398
- Testing
- Inotersen
- Where
- 24 sites in United States, Argentina and 8 more
- Volunteers
- 173 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Chronic Pain, Intractable Pain
Study to Evaluate Automated Intensity Management in Patients Undergoing a BSC SCS Temporary Trial
The purpose of the study is to assess the feasibility of using information extracted from physiologic signals to automatically adjust stimulation in patients undergoing Spinal Cord Stimulation (SCS).
- Conditions
- Chronic Pain, Intractable Pain, Low Back Pain, Pain, Neuropathic
- Trial name
- AIM (NCT04909593)
- Testing
- Spinal Cord Stimulation
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Boston Scientific Corporation
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
This is a 2-part study. In Part 1 of the study, subjects will undergo a pain reporting training program in which a painful stimulus will be applied to the subject's hand, and the subjects will be asked to report how painful the…
- Trial name
- NCT01928381
- Testing
- AZD5213 + pregabalin, pregabalin capsules
- Where
- 9 sites in United States
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Diabetic Peripheral Neuropathy, Pain
A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)
The purpose of the study is to assess efficacy and safety of a single treatment of Capsaicin 8% transdermal delivery system in reducing pain from damaged nerves (neuropathic pain) caused by diabetes.
- Trial name
- STEP (NCT01533428)
- Testing
- Capsaicin 8%
- Where
- 29 sites in United States
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc